Key result
Macrophage mTORC1 activation preserves LVEF at ~81% and reduces inflammation following ischemia-reperfusion injury in mice.
Why the study?
Studies report conflicting net influences of mTOR on macrophage phenotype and functionality following ischemia-reperfusion injury, suggesting dependence on disease context and downstream signaling.
Does constitutive macrophage-specific mTORC1 activation via TSC2 deletion protect against cardiac ischemia-reperfusion injury in mice?
Does constitutive macrophage-specific mTORC1 activation via TSC2 deletion protect against cardiac ischemia-reperfusion injury in mice?
Constitutive macrophage-specific mTORC1 activation via TSC2 deletion protects against cardiac ischemia-reperfusion injury by increasing GPNMB expression and reducing pro-inflammatory cell infiltration.
Answers are grounded in this paper and cite their sources.
Macrophage mTORC1 activation shapes post-I/R inflammation in mice; leaves open human relevance and therapeutic targeting.
Introduction Macrophages (MΦ) modulate both myocardial inflammatory and reparative phases following ischemia-reperfusion (I/R) injury. The mechanistic target of rapamycin (mTOR) is thought to play an important role in MΦ phenotype and functionality, but studies report conflicting net influences suggesting dependence on disease context and downstream signaling. Here, we tested the impact of MΦ with constitutive mTORC1 activation induced by targeted deletion of tuberous sclerosis complex 2 (TSC2) on cardiac responses to I/R injury. Methods/Results Myeloid TSC2 depleted (MΦ TSC2-/- ) mice were generated by crossing Lys2 Cre x TSC2 flx/flx . Bone-marrow derived MΦ TSC2-/- vs control MΦ had basal increased mTORC1 and reduced mTORC2 activity. MΦ TSC2-/- were differentially responsive to stimulation by lipopoly- saccharide/IFN-γ or IL-4 in vitro , and all disparities were prevented by rapamycin confirming the model. In vivo, MΦ TSC2-/- mice were strongly protected against I/R injury, with minimal change in ejection fraction, less LV dilation, hypertrophy, lung edema, or activation of stress/pro fibrotic genes. Mice pre-treated with anti-LY6G Ab to deplete neutrophils were still similarly protected, suggesting that the impact was primarily related to MΦ. MΦ TSC2-/- mice had less myocardial pro- inflammatory macrophages (CCR2 + MHC-II hi ), LY6C + monocytes, neutrophils, and CD8 + T cells 5 days post-I/R, and fewer CCR2 + but more CCR2 - MΦ 2 weeks post I/R. Both MΦ TSC2-/- in vitro and in vivo post I/R phenotypes were converted to WT by rapamycin, supporting mTORC1 dependence. Lastly, synthesis of glycoprotein nonmetastatic melanoma protein B (GPNMB), a principally MΦ anti-inflammatory secreted protein protective against myocardial infarction was enhanced in MΦ TSC2-/- macrophages and hearts following I/R in an mTORC1 dependent manner. Conclusion: Constitutive macrophage-specific mTORC1 activation via TSC2 deletion reduces pro-inflammatory cell infiltration, increases GPNMB protein expression and preserves heart function following I/R injury. Rapamycin eliminates these effects. These results identify a cardioprotective mTORC1-GPNMB signaling nexus in MΦ in vivo.
No takes yet. Share an insight, caveat, or question.
Keykhaei et al. (2025) studied Cardiac Ischemia-Reperfusion Injury. Macrophage-specific TSC2 deletion vs. Littermate TSC2fl/fl mice (WT) was evaluated on Ejection fraction at 4 weeks post-ischemia-reperfusion (p=6.3e-9). Constitutive macrophage-specific mTORC1 activation via TSC2 deletion preserved ejection fraction and reduced pro-inflammatory cell infiltration following cardiac ischemia-reperfusion injury in mice.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: